AR020017A1 - Integracion osea - Google Patents

Integracion osea

Info

Publication number
AR020017A1
AR020017A1 ARP990106158A ARP990106158A AR020017A1 AR 020017 A1 AR020017 A1 AR 020017A1 AR P990106158 A ARP990106158 A AR P990106158A AR P990106158 A ARP990106158 A AR P990106158A AR 020017 A1 AR020017 A1 AR 020017A1
Authority
AR
Argentina
Prior art keywords
integration
endoprotesis
osea
salts
ibandronate
Prior art date
Application number
ARP990106158A
Other languages
English (en)
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of AR020017A1 publication Critical patent/AR020017A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)

Abstract

Uso de ácido ibandronico (ácido 1-hidroxi-3-(N-metil-N-pentil)aminopropil-1,1-difosfonico) o sales fisiologicamente compatibles o ésteres del mismo paramejorar la integracion osea de endoprotesis ancladas libres de cemento. Ibandronato o las salesde l mismo se administran durante un tiempo corto,inmediatamente después de la insercion de una endoprotesis, con el resultado sorprendente de que se obtiene la estabilidad secundaria del implante en solo 5semanas o menos después de la operacion.
ARP990106158A 1998-12-04 1999-12-03 Integracion osea AR020017A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19855976 1998-12-04

Publications (1)

Publication Number Publication Date
AR020017A1 true AR020017A1 (es) 2002-03-27

Family

ID=7889968

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106158A AR020017A1 (es) 1998-12-04 1999-12-03 Integracion osea

Country Status (17)

Country Link
US (1) US6680307B1 (es)
EP (2) EP1614422A3 (es)
JP (1) JP3793023B2 (es)
KR (1) KR100453779B1 (es)
CN (1) CN1173704C (es)
AR (1) AR020017A1 (es)
AT (1) ATE303153T1 (es)
AU (1) AU756540B2 (es)
BR (1) BR9915927A (es)
CA (1) CA2353528C (es)
DE (1) DE69927048T2 (es)
DK (1) DK1135140T3 (es)
ES (1) ES2247842T3 (es)
PT (1) PT1135140E (es)
TR (1) TR200101546T2 (es)
WO (1) WO2000033849A1 (es)
ZA (1) ZA200104140B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004038A1 (en) * 2000-07-12 2002-01-17 Hopital Orthopedique De La Suisse Romande Active biocoating for bone implant
EP1228761A3 (en) * 2001-02-01 2003-01-15 Riderway Corporation Liquid pharmaceutical composition for treating bone diseases
CN100479823C (zh) * 2001-12-21 2009-04-22 宝洁公司 双膦酸盐在制造药物套盒中的用途以及用于增加骨质的套盒
ES2532393T3 (es) * 2002-05-10 2015-03-26 F. Hoffmann-La Roche Ag Acidos bisfosfónicos para tratamiento y prevención de osteoporosis
NZ536273A (en) * 2002-12-20 2007-08-31 Hoffmann La Roche High dose ibandronate formulation
EP1508343B1 (en) * 2003-08-21 2015-11-04 AddBIO AB Bisphosponate coated implant device and method therefor
RU2387661C2 (ru) * 2005-02-01 2010-04-27 Ф.Хоффманн-Ля Рош Аг Полиморфная модификация в ибандроната
CA2594802C (en) * 2005-02-01 2012-11-27 Uwe Eiermann Ibandronate polymorph a
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
CA2151240A1 (en) * 1992-12-23 1994-07-07 Donna T. Whiteford Biophosphonate/estrogen therapy for treating and preventing bone loss
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
FI92465C (fi) 1993-04-14 1994-11-25 Risto Tapani Lehtinen Menetelmä endo-osteaalisten materiaalien käsittelemiseksi
US5646134A (en) 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
GB9408775D0 (en) 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
WO1996039107A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
JP4269015B2 (ja) * 1996-12-13 2009-05-27 オステオスクリーン アイピー， エルエルシー 骨の成長を刺激する組成物および方法

Also Published As

Publication number Publication date
ATE303153T1 (de) 2005-09-15
EP1135140A1 (en) 2001-09-26
CA2353528A1 (en) 2000-06-15
DE69927048T2 (de) 2006-06-08
US6680307B1 (en) 2004-01-20
JP2002531509A (ja) 2002-09-24
KR20010093137A (ko) 2001-10-27
AU1557700A (en) 2000-06-26
EP1135140B1 (en) 2005-08-31
BR9915927A (pt) 2001-08-21
EP1614422A2 (en) 2006-01-11
ES2247842T3 (es) 2006-03-01
ZA200104140B (en) 2002-08-21
DK1135140T3 (da) 2005-12-19
WO2000033849A1 (en) 2000-06-15
CN1329495A (zh) 2002-01-02
KR100453779B1 (ko) 2004-10-20
DE69927048D1 (de) 2005-10-06
JP3793023B2 (ja) 2006-07-05
EP1614422A3 (en) 2009-02-18
PT1135140E (pt) 2005-10-31
AU756540B2 (en) 2003-01-16
CN1173704C (zh) 2004-11-03
TR200101546T2 (tr) 2001-11-21
CA2353528C (en) 2007-04-24

Similar Documents

Publication Publication Date Title
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
AR020017A1 (es) Integracion osea
AU7888398A (en) Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
DE69328973D1 (de) Intraokulare prothese
ATE211387T1 (de) Oral 1alpha-hydroxyprevitamin d
MX9207349A (es) Metodos para el tratamiento de osteoporosis utilizando bisfosfonatos y hormona de paratiroides.
ES2158108T3 (es) Vacunacion in ovo contra la coccidiosis.
ATE119777T1 (de) Behandlungsmethoden für osteoporose.
YU27395A (sh) Mokra granulacija formulacije za bisfosfinske kiseline
MA22915A1 (fr) Methodes de traitement de l'osteoporose pour utilisation de faibles doses de phosphonates.
CA2035179A1 (en) Pharmaceutical compositions containing insoluble salts of bisphosphonic acids
ES2054108T3 (es) Un metodo para estabilizar estropipato en una forma de dosificacion farmaceutica.
EE200300017A (et) Otsese pressimisega saadud tablett, mis sisaldab toimeainena 4-amino-1-hüdroksübutülideen-1,1-bisfosfoonhapet
IS1801B (is) Pýridýlbisfosfónöt til notkunar sem efni til lækninga
DE59809717D1 (de) Implantat, insbesondere zahnwurzelimplantat
AR038041A1 (es) Metodo para el tratamiento de trastornos oseos
ES2152865A1 (es) Utilizacion de bisfosfonatos en la preparacion de composiciones farmaceuticas para uso intramuscular.
IT1253255B (it) Strumentario chirurgico per l'impianto,il fissaggio in opera e l'estrazione di chiodi intermidollari
NO308195B1 (no) Anvendelse av benzydamin til fremstilling av et legemiddel ved behandling av patologiske tilstander forÕrsaket av TNF
ES2073924T3 (es) Nueva calcitonina y metodo para la preparacion y uso de la misma.
GB0128052D0 (en) Compounds
AR000694A1 (es) Implante y conector para protesis intraoral, metodo de implantacion oseointegrada que utiliza el implante, tapones accesorios para uso con elmetodo de implantacion e infraestructura para implantosoportar la protesis intraoral.
UY23640A1 (es) Procedimiento de elaboracion de fosfato de levamisol inyectable
HUP0004653A2 (hu) Biszfoszfonátok alkalmazása csontreszorpció gátlására szolgáló gyógyszerkészítmények előállítására
IT7860904V0 (it) Scarpa femminile nella quale la suola, il tacco e la zeppa metatarsale sono apprestati dall'accoppiamento di due pezzi, caratterizzata dal fatto che la suola e' incassata all'esterno della zeppa metatarsale per una lunghezza preponderante di quest'ultima.

Legal Events

Date Code Title Description
FC Refusal